WallStSmart

Workiva Inc (WK)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Workiva Inc generates 242% more annual revenue ($884.57M vs $258.90M). WK leads profitability with a -3.0% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

WK

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 6.0Quality: 4.8
Piotroski: 4/9Altman Z: 0.30

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

WKUndervalued (+16.3%)

Margin of Safety

+16.3%

Fair Value

$77.57

Current Price

$53.91

$23.66 discount

UndervaluedFair: $77.57Overvalued
ZEPPUndervalued (+48.6%)

Margin of Safety

+48.6%

Fair Value

$46.70

Current Price

$17.47

$29.23 discount

UndervaluedFair: $46.70Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

WK1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
19.5%8/10

19.5% revenue growth

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

WK4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Operating MarginProfitability
3.3%3/10

Operating margin of 3.3%

Return on EquityProfitability
-2763.0%2/10

ROE of -2763.0% — below average capital efficiency

Altman Z-ScoreHealth
0.302/10

Distress zone — elevated risk

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : WK

The strongest argument for WK centers on Revenue Growth. Revenue growth of 19.5% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : WK

The primary concerns for WK are EPS Growth, Operating Margin, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

WK profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SOFTWARE - APPLICATION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 32/100) and 43.0% revenue growth. WK offers better value entry with a 16.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Workiva Inc

TECHNOLOGY · SOFTWARE - APPLICATION · USA

Workiva Inc. provides global cloud-based compliance and regulatory reporting solutions. The company is headquartered in Ames, Iowa.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?